Sat, Aug 2, 2014, 6:16 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Acorda Therapeutics, Inc. (ACOR) Message Board

  • fastmoneypete fastmoneypete Oct 8, 2012 11:16 AM Flag

    Group Health negative AMPYRA review updated on October 4, 6:53pm

    Looks like another Questcor in the making.
    Group Health updates coverage and withdraws Ampyra for MS, which was revised on Thursday, October 4 at 6:53pm and published today on their website - so this is a new update! Search Ampyra and you can download the pdf. Then go to Properties of the downloaded file to verify the revision date (October 4) for this data.:

    Drug Name: Dalfampridine (Ampyra) Dosage, Route: Tablet, oral
    Drug Class/Indication: Multiple sclerosis
    Decision: Add criteria.
    GH Closed Formulary GH Open Formulary Medicare Part D
    Formulary Status Non-formulary with
    criteria
    Tier 3 with criteria Tier 4 (non-preferred)
    Drug Criteria:
    Medical necessity review required.
    Rationale:
    Dalfampridine provides outcomes of questionable clinical significance and lacks long-term safety data

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ACOR
28.45-0.82(-2.80%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Icahn Enterprises, L.P.
NasdaqGSFri, Aug 1, 2014 3:59 PM EDT
Marriott International, Inc.
NasdaqGSFri, Aug 1, 2014 4:00 PM EDT